Market Closed -
Deutsche Boerse AG
02:04:46 2024-07-05 am EDT
|
5-day change
|
1st Jan Change
|
1.05
EUR
|
0.00%
|
|
-0.94%
|
-24.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,844
|
6,822
|
11,234
|
9,593
|
10,162
|
7,517
|
-
|
-
|
Enterprise Value (EV)
1 |
7,877
|
4,978
|
8,960
|
7,350
|
7,784
|
4,684
|
4,885
|
4,208
|
P/E ratio
|
17.8
x
|
12.5
x
|
18.4
x
|
14.9
x
|
18.7
x
|
11.6
x
|
8.95
x
|
8.8
x
|
Yield
|
1.96%
|
2.94%
|
2.09%
|
2.88%
|
2.72%
|
4.45%
|
5.18%
|
5.79%
|
Capitalization / Revenue
|
6.87
x
|
5.19
x
|
7.22
x
|
5.54
x
|
6.66
x
|
4.33
x
|
3.78
x
|
3.23
x
|
EV / Revenue
|
5.5
x
|
3.78
x
|
5.76
x
|
4.25
x
|
5.1
x
|
2.7
x
|
2.46
x
|
1.81
x
|
EV / EBITDA
|
11
x
|
7.19
x
|
11.3
x
|
8.88
x
|
11.4
x
|
5.46
x
|
4.88
x
|
3.52
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.7
x
|
2.26
x
|
3.29
x
|
2.66
x
|
2.63
x
|
1.78
x
|
1.63
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
837,100
|
837,100
|
837,100
|
837,100
|
837,100
|
837,100
|
-
|
-
|
Reference price
2 |
11.76
|
8.150
|
13.42
|
11.46
|
12.14
|
8.980
|
8.980
|
8.980
|
Announcement Date
|
3/24/20
|
3/11/21
|
3/9/22
|
3/13/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,433
|
1,315
|
1,556
|
1,731
|
1,525
|
1,735
|
1,988
|
2,328
|
EBITDA
1 |
717.2
|
691.9
|
793.8
|
827.8
|
685.5
|
858
|
1,000
|
1,197
|
EBIT
1 |
652
|
669.4
|
778.5
|
811.6
|
624.1
|
777.8
|
912.9
|
1,084
|
Operating Margin
|
45.51%
|
50.89%
|
50.02%
|
46.88%
|
40.93%
|
44.83%
|
45.91%
|
46.56%
|
Earnings before Tax (EBT)
1 |
689.2
|
685.9
|
778.4
|
826
|
687.8
|
832.8
|
983.5
|
1,131
|
Net income
1 |
556.1
|
542.5
|
607.8
|
645.9
|
540.4
|
652
|
758.1
|
857.7
|
Net margin
|
38.82%
|
41.24%
|
39.06%
|
37.31%
|
35.44%
|
37.58%
|
38.13%
|
36.84%
|
EPS
2 |
0.6600
|
0.6500
|
0.7300
|
0.7700
|
0.6500
|
0.7750
|
1.003
|
1.020
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.2300
|
0.2400
|
0.2800
|
0.3300
|
0.3300
|
0.4000
|
0.4650
|
0.5200
|
Announcement Date
|
3/24/20
|
3/11/21
|
3/9/22
|
3/13/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,967
|
1,845
|
2,274
|
2,243
|
2,378
|
2,833
|
2,633
|
3,309
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
20%
|
19.1%
|
18.9%
|
18.4%
|
14.5%
|
16.1%
|
17.1%
|
18%
|
ROA (Net income/ Total Assets)
|
17.6%
|
16.6%
|
16.8%
|
-
|
12.5%
|
14%
|
14.4%
|
-
|
Assets
1 |
3,155
|
3,278
|
3,626
|
-
|
4,330
|
4,657
|
5,265
|
-
|
Book Value Per Share
2 |
3.180
|
3.600
|
4.080
|
4.310
|
4.620
|
5.040
|
5.500
|
5.950
|
Cash Flow per Share
2 |
0.6600
|
0.1400
|
0.9300
|
0.6500
|
0.5500
|
0.8900
|
0.8500
|
-
|
Capex
1 |
17
|
12.9
|
23.4
|
38.5
|
21.9
|
59
|
63
|
-
|
Capex / Sales
|
1.19%
|
0.98%
|
1.5%
|
2.22%
|
1.44%
|
3.4%
|
3.17%
|
-
|
Announcement Date
|
3/24/20
|
3/11/21
|
3/9/22
|
3/13/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
8.98
HKD Average target price
13.92
HKD Spread / Average Target +55.07% Consensus |
1st Jan change
|
Capi.
|
---|
| +56.89% | 809B | | +39.52% | 624B | | -6.55% | 351B | | +7.92% | 289B | | +13.74% | 240B | | +13.83% | 220B | | -0.49% | 219B | | +7.94% | 166B | | -2.57% | 157B |
Other Pharmaceuticals
|